CYBN Dana dhuwit perusahaan Cybin Inc.

Cybin Inc. (CYBN) leads the development of innovative psychedelics for anxiety treatment using unique delivery methods. The GURU.Markets terminal displays a chart of the company's cash position, where the 0.08 mark records this metric. The business's liquidity is independent of GDP cycles, and its growth strategy relies on securing a major pharma partner to fund future research stages.
Cybin Inc. (CYBN) - rincian metrik lan laporan keuangan

Cybin Inc. focuses on developing innovative psychedelics for the treatment of depression. This metric aggregates liquid assets, determining the company's ability to fund costly clinical trials without external borrowing. Sufficient reserves minimize the risk of default given the binary outcomes associated with the development of its sole key product. By analyzing cash asset dynamics, an investor can assess the burn rate and the business's survival horizon.